Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03067935
NCT03067935No Longer AvailableNot Applicable

Individual Patient Expanded Access-Glembatumumab Vedotin

Celldex Therapeutics0 sitesStarted: March 1, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
No Longer Available
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to glembatumumab vedotin in patients with gpNMB expressing triple negative breast cancer will be considered.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The patient is 18 years of age or older.
  • •The patient has histologically confirmed, gpNMB expressing, metastatic triple-negative breast cancer
  • •Overexpression of gpNMB in at least one tumor sample as determined by a Sponsor approved laboratory using IHC methods
  • •The patient does not have abnormal organ function, active autoimmune disease, active infections or additional concurrent conditions that would compromise the patient's ability to safely receive glembatumumb vedotin.
  • •The patient is not eligible for or cannot access ongoing glembatumumab vedotin clinical trials
  • •The patient does not qualify for, or cannot access, other comparable or satisfactory alternative therapy for triple negative breast cancer.
  • •The patient is able to read and understand, and has signed a patient informed consent form, which outlines the nature of the proposed treatment and the anticipated benefits and risks of treatment with glembatumumab vedotin.

Exclusion Criteria

  • •History of allergic reactions attributed to compounds of similar composition to glembatumumab vedotin, MMAE, dolastatin or auristatin.
  • •Pregnant or breast-feeding women, and women or men who are not willing to use effective contraception during the time from signing of informed consent through two months after the last dose of glembatumumab vedotin treatment.
  • •The patient was previously treated with glembatumumab vedotin or previously enrolled on the METRIC trial (regardless of which arm they were randomized to).
  • •Any underlying medical condition that, in the investigator's or Sponsor's opinion, will make the administration of Glembatumumab vedotin hazardous to the patient, or would obscure the interpretation of adverse events.

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

No Longer Available
Not Applicable
Expanded Access (Compassionate Use) Treatment Protocol RindopepimutRecurrent GBM
NCT03068650Celldex Therapeutics
Unknown
Not Applicable
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCISpinal Cord Injury at C5-C7 Level
NCT03925649Hope Biosciences LLC
No Longer Available
Not Applicable
Expanded Access to Elotuzumab (Empliciti) for Multiple MyelomaMultiple Myeloma
NCT03126617Bristol-Myers Squibb
Available
Not Applicable
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAcute Lymphoblastic LeukemiaMantle Cell Lymphoma
NCT05776134Kite, A Gilead Company
Available
Not Applicable
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular Lymphoma
NCT05776160Kite, A Gilead Company